The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol
and vilanterol) that are single enantiomers of the (R)-configuration. All have a near full …

Introduction: A fixed-dose inhalation of a long-acting β-agonist (LABA) and inhaled
corticosteroids (ICS) is commonly recommended for moderate to severe asthmatic patients …

Several studies suggested an association between the regular use of β 2-agonists and
asthma deaths. Whether this association represents adverse effects of β-agonist use or is …

Concerns about the safety of long-acting β2-agonist (LABA) therapy, has led to the
appearance of multiple publications and recommendations. This review critically examines …

The combination of long-acting beta-agonist (LABA) bronchodilators with inhaled
corticosteroids (ICSs) has been shown to be an extremely effective treatment for asthma …

Bronchodilators are central in the symptomatic management of asthma. It is likely that the
once-daily dosing of a bronchodilator would be a significant convenience and probably a …

OBJECTIVE: To review the more recent literature addressing the issue of whether β2-
agonists can worsen asthma and/or increase the risk of severe exacerbations and death …

There has been a real interest recently in developing once-daily β2-adrenoceptor agonists
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …

After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …

Abstract Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for
prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids …